Efficacy of Brivaracetam in children with epilepsy
Copyright © 2021 Elsevier B.V. All rights reserved..
BACKGROUND AND OBJECTIVES: To determine the efficacy, tolerance, and safety of BRV in children with epilepsy.
METHODS: A retrospective study of patients with epilepsy who received treatment with BRV before age 16 years and underwent a minimum follow-up of 3 months.
METHOD AND RESULTS: Sixty-six patients were included in the study. Patients received BRV at a mean age of 8.8 years (range 1-16 years). The majority (93.4 %) had refractory epilepsy, 27 with epileptic encephalopathy. The median maximum dose used was 4.3 mg/kg/day. In 30.3 % of the cases, seizure frequency was reduced by over 50 %, and 9 % remained seizure-free. Greater efficacy was observed in those patients who received higher doses and when a direct switch from levetiracetam (LEV) to BRV was performed. The ineffectiveness of LEV was not related to a failure to respond to BRV treatment. Side effects were identified in 24.2 % of the cases, the most frequent being irritability and drowsiness.
CONCLUSIONS: BRV appears to be an effective, safe, and well-tolerated AED in children with refractory epilepsy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:177 |
|---|---|
| Enthalten in: |
Epilepsy research - 177(2021) vom: 01. Nov., Seite 106757 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferragut Ferretjans, Fernando [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticonvulsants |
|---|
| Anmerkungen: |
Date Completed 29.03.2022 Date Revised 01.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eplepsyres.2021.106757 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330722867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330722867 | ||
| 003 | DE-627 | ||
| 005 | 20231225211909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eplepsyres.2021.106757 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM330722867 | ||
| 035 | |a (NLM)34530305 | ||
| 035 | |a (PII)S0920-1211(21)00210-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferragut Ferretjans, Fernando |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of Brivaracetam in children with epilepsy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: To determine the efficacy, tolerance, and safety of BRV in children with epilepsy | ||
| 520 | |a METHODS: A retrospective study of patients with epilepsy who received treatment with BRV before age 16 years and underwent a minimum follow-up of 3 months | ||
| 520 | |a METHOD AND RESULTS: Sixty-six patients were included in the study. Patients received BRV at a mean age of 8.8 years (range 1-16 years). The majority (93.4 %) had refractory epilepsy, 27 with epileptic encephalopathy. The median maximum dose used was 4.3 mg/kg/day. In 30.3 % of the cases, seizure frequency was reduced by over 50 %, and 9 % remained seizure-free. Greater efficacy was observed in those patients who received higher doses and when a direct switch from levetiracetam (LEV) to BRV was performed. The ineffectiveness of LEV was not related to a failure to respond to BRV treatment. Side effects were identified in 24.2 % of the cases, the most frequent being irritability and drowsiness | ||
| 520 | |a CONCLUSIONS: BRV appears to be an effective, safe, and well-tolerated AED in children with refractory epilepsy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiepileptic drug | |
| 650 | 4 | |a Brivaracetam | |
| 650 | 4 | |a Encephalophaty epilepsy | |
| 650 | 4 | |a Focal epilepsy | |
| 650 | 4 | |a Manegment epilepsy | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Pyrrolidinones |2 NLM | |
| 650 | 7 | |a brivaracetam |2 NLM | |
| 650 | 7 | |a U863JGG2IA |2 NLM | |
| 700 | 1 | |a Soto Insuga, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardino Cuesta, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Cantarín Extremera, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Duat Rodriguez, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Legido, María Jiménez |e verfasserin |4 aut | |
| 700 | 1 | |a González Alguacil, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Furones García, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez Solana, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Cantero, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz Falcó, Maria-Luz |e verfasserin |4 aut | |
| 700 | 1 | |a García Peñas, Juan José |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epilepsy research |d 1995 |g 177(2021) vom: 01. Nov., Seite 106757 |w (DE-627)NLM013010581 |x 1872-6844 |7 nnns |
| 773 | 1 | 8 | |g volume:177 |g year:2021 |g day:01 |g month:11 |g pages:106757 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eplepsyres.2021.106757 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 177 |j 2021 |b 01 |c 11 |h 106757 | ||